Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v13-FR Version v7-FR
Language French French
Date Updated 2024-03-27 2023-11-13
Drug Identification Number 02230593 02230593
Brand name NEOSTIGMINE OMEGA NEOSTIGMINE OMEGA
Common or Proper name Neostigmine Methylsulfate Injection USP Neostigmine Methylsulfate Injection USP
Company Name OMEGA LABORATORIES LIMITED OMEGA LABORATORIES LIMITED
Ingredients NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE
Strength(s) 0.5MG 0.5MG
Dosage form(s) LIQUID LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 10 x 10mL vial /fiole 10 x 10mL vial /fiole
ATC code N07AA N07AA
ATC description PARASYMPATHOMIMETICS PARASYMPATHOMIMETICS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-08-03 2023-08-03
Estimated end date 2024-03-28 2024-05-15
Actual end date 2024-03-26
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments